ContraVir Pharmaceuticals Inc Receives a Buy from Maxim Group

By Carrie Williams

Maxim Group analyst Gabrielle Zhou reiterated a Buy rating on ContraVir Pharmaceuticals Inc (NASDAQ: CTRV) today and set a price target of $4. The company’s shares opened today at $1.68.

Zhou observed:

“ContraVir announced new data presentation of TXL (Tenofovir Exalidex, formerly CMX157, a prodrug of tenofovir or Viread, marketed by Gilead [GILD- $65.93-Hold]) and CRV431 (a cyclophilin inhibitor) at EASL the International Liver Congress 2017 in Amsterdam, The Netherlands from April 19 – 23, 2017.”

According to TipRanks.com, Zhou is a 1-star analyst with an average return of -1.5% and a 31.4% success rate. Zhou covers the Healthcare sector, focusing on stocks such as Sciclone Pharmaceuticals, Mateon Therapeutics Inc, and CASI Pharmaceuticals.

ContraVir Pharmaceuticals Inc has an analyst consensus of Moderate Buy.

Based on ContraVir Pharmaceuticals Inc’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $0 and GAAP net loss of $4.51 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $3.92 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ContraVir Pharmaceuticals, Inc. is a development stage biopharmaceutical company which is focused primarily on the development of drugs to treat herpes zoster or shingles. The company currently developing a compound called FV-100 for the treatment of shingles. It is also developing CMX157, a potent analog of the successful antiviral drug tenofovir DF. ContraVir Pharmaceuticals was founded on May 15, 2013 and is headquartered in Edison, NJ.